Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 40 of 110 Updated Nov 17, 2026

Tesofensine

NS2330

PHASE 2/3 (MIXED) · TRIPLE MONOAMINE REUPTAKE INHIBITOR (NON-PEPTIDE)

▓ 89 indexed citations across PubMed (46), ClinicalTrials.gov (13), EuropePMC (30).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

89 citations across 6 tiers

Tap any tier to jump to that section of the bibliography.

Background

Tesofensine (NS2330) is a serotonin–norepinephrine–dopamine reuptake inhibitor from the phenyltropane family of drugs, which is being developed for the treatment of obesity. Tesofensine was originally developed by a Danish biotechnology company, NeuroSearch, who transferred the rights to Saniona in 2014.

→ Wikipedia

Mechanism of action

Inhibits reuptake of norepinephrine, dopamine, serotonin in CNS

Researched effects

Weight loss ~10% Phase 2; appetite suppression

Reported efficacy (trial readout)

  • Weight Loss 10%

    ~10% (Phase 2)

    Phase 2

Trial-efficacy data current as of November 16, 2026.

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

0.25-1 mg oral daily

Known concerns

Tachycardia; hypertension; mood effects; insomnia

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Weight loss produced by tesofensine in patients with Parkinson's or Alzheimer's disease.

    Obesity (Silver Spring, Md.) · 2008 — META-ANALYSES · AUTHORITY 92.8

  2. Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

    European journal of endocrinology · 2022 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.2

  3. The effect of tesofensine on appetite sensations.

    Obesity (Silver Spring, Md.) · 2012 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.2

  4. Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users.

    Clinical pharmacology and therapeutics · 2010 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.0

  5. Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.

    The AAPS journal · 2010 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.0

  6. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men.

    International journal of obesity (2005) · 2010 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.0

  7. 48 Weeks, Study to Evaluate Overall Safety and Tolerability of Co-administration of Tesofensine and Metoprolol in Subjects With Hypothalamic Injury-induced Obesity (HIO)

    2019 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 72.9

  8. A quantitative enterohepatic circulation model: development and evaluation with tesofensine and meloxicam.

    Clinical pharmacokinetics · 2009 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.9

  9. [The effect of tesofensine on body weight and body composition in obese subjects--secondary publication].

    Ugeskrift for laeger · 2009 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.9

  10. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial.

    Lancet (London, England) · 2008 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.8

Full citation library

Year distribution

Meta-Analyses

1
  1. 1.

    Astrup A, Meier DH, Mikkelsen BO, Villumsen JS, et al. · Obesity (Silver Spring, Md.) · 2008 · PMID 18356831

    Tesofensine (TE) is a norepinephrine, dopamine, and serotonin reuptake inhibitor. We conducted a meta-analysis of TE's effect on body weight in trials investigating its potential for treatment of Parkinson's or Alzheimer's disease. Four randomized, double-blind, multicenter trials compared TE (n = 740) and placebo (n = 228), two in each disease. Patients received oral TE or placebo once daily for 14 weeks without any weight loss program. Results were adjusted for baseline values, age, and study.…

Randomised Controlled Trials

11
  1. 2.

    Lehr T, Staab A, Tillmann C, Trommeshauser D, et al. · British journal of clinical pharmacology · 2007 · PMID 17324246

    To develop a population pharmacokinetic model for NS2330 and its major metabolite M1 based on data from a 14 week proof of concept study in patients with Alzheimer's disease, and to identify covariates that might influence the pharmacokinetic characteristics of the drug and/or its metabolite. Plasma data from 320 subjects undergoing multiple oral dosing, and consisting of 1969 NS2330 and 1714 metabolite concentrations were fitted simultaneously using NONMEM. Plasma concentration-time profiles of…

  2. 3.

    Schoedel KA, Meier D, Chakraborty B, Manniche PM, et al. · Clinical pharmacology and therapeutics · 2010 · PMID 20520602

    Tesofensine is a (triple) reuptake inhibitor of noradrenaline, dopamine, and serotonin that is in development for the treatment of obesity. The abuse potential of triple reuptake inhibitors is not yet known, and so this study was undertaken to evaluate the potential abuse-related effects of tesofensine in humans. It was designed as a single-dose, randomized, double-blind, crossover study involving tesofensine vs. placebo, D-amphetamine (positive control for dopaminergic/stimulant effects), bupro…

  3. 4.

    Lehr T, Staab A, Tillmann C, Trommeshauser D, et al. · Clinical pharmacokinetics · 2009 · PMID 19705923

    Drugs undergoing enterohepatic circulation (EHC) are associated with typical pharmacokinetic characteristics such as multiple-peak phenomenon in the plasma concentration-time profile and prolongation of the apparent elimination half-life (t((1/2))). Currently, versatile pharmacokinetic models are lacking that could test the hypothesis of an EHC for observed multiple-peak phenomenon in pharmacokinetic profiles and its quantitative contribution. The aim of this analysis was to accomplish a model t…

  4. 5.

    Astrup A, Madsbad S, Breum L, Jensen TJ, et al. · Lancet (London, England) · 2008 · PMID 18950853

    Weight-loss drugs produce an additional mean weight loss of only 3-5 kg above that of diet and placebo over 6 months, and more effective pharmacotherapy of obesity is needed. We assessed the efficacy and safety of tesofensine-an inhibitor of the presynaptic uptake of noradrenaline, dopamine, and serotonin-in patients with obesity. We undertook a phase II, randomised, double-blind, placebo-controlled trial in five Danish obesity management centres. After a 2 week run-in phase, 203 obese patients…

  5. 6.

    Rascol O, Poewe W, Lees A, Aristin M, et al. · Archives of neurology · 2008 · PMID 18474731

    To assess the safety and efficacy of tesofensine, a triple monoamine reuptake inhibitor, in patients with advanced Parkinson disease (PD). A pilot phase 2, randomized, double-blind, placebo-controlled, parallel-group trial. The study occurred in hospital-based outpatient clinics and in clinical trial units. Patients with advanced PD and levodopa-related motor fluctuations were enrolled. Tesofensine (0.125, 0.25, 0.5, or 1 mg) or placebo tablets were administered once daily for 14 weeks. Coprimar…

  6. 7.

    Nielsen AL, Larsen TM, Madsbad S, Breum L, et al. · Ugeskrift for laeger · 2009 · PMID 19824222

    Results from a phase II trial with Tesofensine for treatment of obesity are presented. In total 203 obese persons were randomised to treatment with Tesofensine 0.25, 0.5, or 1.0 mg, or placebo daily for 24 weeks. Treatment with Tesofensine resulted in a mean weight reduction of 4.5, 9.2 and 10.6% higher than that of placebo for 0.25, 0.5 and 1.0 mg, respectively. Tesofensine 0.5 mg might have the potential to produce a weight loss twice that of currently approved anti-obesity drugs. Findings of…

  7. 8.

    Gilbert JA, Gasteyger C, Raben A, Meier DH, et al. · Obesity (Silver Spring, Md.) · 2012 · PMID 21720440

    Tesofensine (TE), an inhibitor of monoamine presynaptic reuptake, has produced twice the weight loss seen with currently marketed drugs. However, its long term effect on appetite in humans has not been studied. A multicentre phase II trial was divided into two parts (24 weeks each). Part 1 had a randomized, double-blind, placebo-controlled design and Part 2, an open-labeled, single-group, uncontrolled design. A drug-free period (12 ± 3 weeks) separated them. In Part 1, participants (n = 158) wer…

  8. 9.

    Lehr T, Staab A, Trommeshauser D, Schaefer HG, et al. · The AAPS journal · 2010 · PMID 20077053

    Effective therapeutic options for Alzheimer's disease (AD) are limited and much research is currently ongoing. The high attrition rate in drug development is a critical issue. Here, the quantitative pharmacology approach (QP-A) and model-based drug development (MBDD) provide a valuable opportunity to support early selection of the most promising compound and facilitate a fast, efficient, and rational drug development process. The aim of this analysis was to exemplify the QP-A by eventually predi…

  9. 10.

    Huynh K, Klose M, Krogsgaard K, Drejer J, et al. · European journal of endocrinology · 2022 · PMID 35294397

    Hypothalamic injury often leads to rapid, intractable weight gain causing hypothalamic obesity, which is associated with increased risk of cardiovascular and metabolic morbidity and mortality. There are no approved or effective pharmacological treatments for hypothalamic obesity, and conventional lifestyle management remains ineffective. To investigate the safety and efficacy of Tesomet (0.5 mg tesofensine/50 mg metoprolol) in adults with hypothalamic obesity. Twenty-one adults with hypothalamic…

  10. 11.

    Hauser RA, Salin L, Juhel N, Konyago VL · Movement disorders : official journal of the Movement Disorder Society · 2007 · PMID 17149725

    The objective of this study was to evaluate the efficacy and safety of three daily dosages of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) compared to placebo as monotherapy in early Parkinson's disease (PD). In MPTP (1-methyl 4-phenyl-tetrahydropyridine 1,2,3,6)-lesioned marmosets, dopamine reuptake inhibitors have been demonstrated to reverse parkinsonian signs without evoking established dyskinesia. NS 2330 inhibits reuptake of dopamine, serotonin, and norepinephrine. We perf…

  11. 12.

    Sjödin A, Gasteyger C, Nielsen AL, Raben A, et al. · International journal of obesity (2005) · 2010 · PMID 20479765

    Tesofensine (TE) is a new drug producing twice the weight loss in obese individuals as seen with currently marketed drugs. It inhibits the presynaptic reuptake of the neurotransmitters noradrenaline, dopamine and serotonin, and is thought to enhance the neurotransmission of all three monoamines. The mechanisms by which it produces weight loss in humans are unresolved. The aim of this study is to investigate the mechanism(s) behind weight reduction by measuring energy expenditure and appetite sen…

Trial Registrations (ClinicalTrials.gov)

13
  1. 13.

    NCT05198362 · Phase 2 · Withdrawn · 2021

    Conditions: Prader-Willi Syndrome

  2. 14.

    NCT05147415 · Phase 2 · Withdrawn · 2021

    Conditions: Hypothalamic Obesity

  3. 15.

    NCT03149445 · Phase 2 · Completed · 2017

    Conditions: Confirmed Genetic Diagnosis of Prader-Willi Syndrome

  4. 16.
  5. 17.

    NCT00394667 · Phase 2 · Completed · 2006

    Conditions: Obesity

  6. 18.

    NCT03488719 · Phase 1 · Completed · 2018

    Conditions: Phase 1

  7. 19.
  8. 20.

    NCT00153010 · Phase 2 · Completed · 2003

    Conditions: Alzheimer Disease

  9. 21.

    NCT00481104 · Phase 2 · Completed · 2007

    Conditions: Obesity

  10. 22.
  11. 23.

    NCT02737891 · Phase 2 · Completed · 2016

    Conditions: Type 2 Diabetes Mellitus

  12. 24.

    NCT00428415 · Phase 1/Phase 2 · Completed · 2007

    Conditions: Obesity

  13. 25.

    NCT03286829 · Phase 1 · Completed · 2017

    Conditions: Healthy Male Subjects

Reviews

14
  1. 26.

    Bello NT, Zahner MR · Current opinion in investigational drugs (London, England : 2000) · 2009 · PMID 19777399

    Tesofensine, a monoamine reuptake inhibitor, is under development by NeuroSearch A/S for the potential treatment of obesity. In vitro, the compound potently blocked dopamine, norepinephrine and serotonin reuptake. Initial development, which was conducted by NeuroSearch in collaboration with Boehringer Ingelheim Corp, demonstrated that although tesofensine was ineffective as a treatment for neurodegenerative conditions, a notable occurrence of unintended weight loss was observed in individuals tr…

  2. 27.

    George M, Rajaram M, Shanmugam E · Journal of cardiovascular pharmacology and therapeutics · 2014 · PMID 24064009

    Obesity has become a growing pandemic of alarming proportions in the developed and developing countries over the last few decades. The most perturbing fact regarding obesity is the increased predisposition for coronary artery disease, congestive heart failure and sudden cardiac death. The modest efficacy of current anti-obesity agents such as orlistat and the increasing withdrawals of several anti-obesity agents such as sibutramine, rimonabant have led to huge gaps in the pharmacotherapy of obes…

  3. 28.

    Thatte U · Current opinion in investigational drugs (London, England : 2000) · 2001 · PMID 11763162

    NeuroSearch is developing NS-2330, a compound that increases the activity of dopamine, norepinephrine and acetylcholine, as a potential therapy for Alzheimer's disease (AD) and Parkinson's disease (PD) [260782]. It is in phase II for AD [355341], and by March 2001 was also in a phase II tolerability trial in PD patients with dyskinesia. Phase III studies are expected to begin in the third quarter of 2002 [413151]. At this time, NeuroSearch was in licensing negotiations with a number of companies…

  4. 29.

    Halford JC, Boyland EJ, Blundell JE, Kirkham TC, et al. · Nature reviews. Endocrinology · 2010 · PMID 20234354

    For obese individuals, successful weight loss and maintenance are notoriously difficult. Traditional drug development fails to exploit knowledge of the psychological factors that crucially influence appetite, concentrating instead on restrictive criteria of intake and weight reduction, allied to a mechanistic view of energy regulation. Drugs are under development that may produce beneficial changes in appetite expression in the obese. These currently include glucagon-like peptide-1 analogs such…

  5. 30.

    Faria AM, Mancini MC, Melo ME, Cercato C, et al. · Arquivos brasileiros de endocrinologia e metabologia · 2010 · PMID 20857056

    Obesity prevalence has risen dramatically over the past decades, which poses a great number of patients at risk of metabolic and cardiovascular complications. Long-term efficacy of lifestyle modification isolated has shown to be modest which, therefore, urges the need of more aggressive interventions such as adjuvant pharmacotherapy or the more radical surgical approach. Bariatric surgery has proven to date to be the most effective treatment, although it may be associated with nutritional and me…

  6. 31.

    Halford JC, Boyland EJ, Lawton CL, Blundell JE, et al. · Drugs · 2011 · PMID 22085383

    The role of serotonin (5-hydroxytryptamine) in appetite control is long established. Serotonergic manipulations reduce food intake in rodents in a manner consistent with satiety. In humans, drugs such as fenfluramine, dexfenfluramine and sibutramine all reduce energy intake, suppress hunger and enhance satiety. Effects on eating behaviour and subjective sensations of appetite are associated with the weight loss-inducing effects of these treatments. Currently, no appetite-suppressing drugs are ap…

  7. 32.

    Coulter AA, Rebello CJ, Greenway FL · Drugs · 2018 · PMID 30014268

    For many years, obesity was believed to be a condition of overeating that could be resolved through counseling and short-term drug treatment. Obesity was not recognized as a chronic disease until 1985 by the scientific community, and 2013 by the medical community. Pharmacotherapy for obesity has advanced remarkably since the first class of drugs, amphetamines, were approved for short-term use. Most amphetamines were removed from the obesity market due to adverse events and potential for addictio…

  8. 33.

    Li X, Bello NT · Expert opinion on pharmacotherapy · 2020 · PMID 31762335

  9. 34.

    Derosa G, Maffioli P · Expert opinion on drug safety · 2012 · PMID 22439841

    Amphetamines, rimonabant and sibutramine licenses as anti-obesity drugs have been withdrawn because of their adverse effects. In fact, orlistat is the only available long-term treatment for obesity. The efficacy and safety of long-term drug therapy is very important in the management obesity; for this reason, the authors decided to conduct a review on the efficacy and safety of current, past and future pharmacotherapies for weight loss. Orlistat is a good choice for the treatment of obesity, bec…

  10. 35.

    Nathan PJ, O'Neill BV, Napolitano A, Bullmore ET · CNS neuroscience & therapeutics · 2011 · PMID 21951371

    Central neurochemical systems including the monoamine, opioid, and cannabinoid systems have been promising targets for antiobesity drugs that modify behavioral components of obesity. In addition to modulating eating behavior, centrally acting antiobesity drugs are also likely to alter emotional behavior and cognitive function due to the high expression of receptors for the neurochemical systems targeted by these drugs within the fronto-striatal and limbic circuitry. This paper reviewed the neuro…

  11. 36.

    Kennett GA, Clifton PG · Pharmacology, biochemistry, and behavior · 2010 · PMID 20688100

    In this review we assess the range of centrally active anorectics that are either in human clinical trials, or are likely to be so in the near future. We describe their weight loss efficacy, mode of action at both pharmacological and behavioural levels, where understood, together with the range of side effects that might be expected in clinical use. We have however evaluated these compounds against the considerably more rigorous criteria that are now being used by the Federal Drugs Agency and Eu…

  12. 37.

    Srivastava G, Apovian C · Current obesity reports · 2018 · PMID 29504049

    Obesity is a global health crisis with detrimental effects on all organ systems leading to worsening disease state and rising costs of care. Persons with obesity failing lifestyle therapies need to be escalated to appropriate pharmacological treatment modalities, medical devices, and/or bariatric surgery if criteria are met and more aggressive intervention is needed. The progression of severe obesity in the patient population coupled with related co-morbidities necessitates the development of no…

  13. 38.

    Wu SS, Frucht SJ · CNS drugs · 2005 · PMID 16142989

    Few neurological diseases have received as much attention and investment in research as Parkinson's disease. Although great strides have been made in the development of agents to treat this neurodegenerative disease, none yet address the underlying problem associated with it, the progressive loss of dopaminergic neurons. Current therapeutic strategies for Parkinson's disease focus primarily on reducing the severity of its symptoms using dopaminergic medications. Although providing substantial be…

  14. 39.

    Hainer V · Casopis lekaru ceskych · 2010 · PMID 21391349

    Pharmacotherapy of obesity should be an integral part of the comprehensive obesity management program which includes diet, exercise and cognitive behavioural intervention. Currently available antiobesity drugs result in only modest weight loss, however it is still accompanied by reduction of cardiometabolic health risks. In the past several antiobesity drugs were removed from the market because of serious adverse effects (psychostimulatory, cardiovascular, pulmonary hypertension, valvular diseas…

Research Articles

49
  1. 40.

    Perez CI, Luis-Islas J, Lopez A, Diaz X, et al. · PloS one · 2024 · PMID 38656972

    Obesity is a major global health epidemic that has adverse effects on both the people affected as well as the cost to society. Several anti-obesity drugs that target GLP-1 receptors have recently come to the market. Here, we describe the effects of tesofensine, a novel anti-obesity drug that acts as a triple monoamine neurotransmitter reuptake inhibitor. Using various techniques, we investigated its effects on weight loss and underlying neuronal mechanisms in mice and rats. These include behavio…

  2. 41.

    Lehr T, Staab A, Trommeshauser D, Schaefer HG, et al. · Clinical pharmacokinetics · 2010 · PMID 20000889

    For compounds with a long elimination half-life, the evaluation of a drug-drug interaction (DDI) study can be challenging. The standard analytical approach of a non-compartmental analysis (NCA) might not be able to detect the full interaction potential and may lead to a significant underestimation of the interaction. The most appropriate method for data analysis might be a semi-mechanistic population pharmacokinetic modelling approach. To accomplish a semi-mechanistic DDI model for a long-elimin…

  3. 42.

    Li Y, Meng Y, Li N, Zhao J, et al. · Nature communications · 2025 · PMID 41392177

    Most first-line pharmacotherapeutic strategies for depression aim to boost serotonin and norepinephrine levels. However, 35% of patients with depression do not respond adequately to these treatments or experience adverse side effects. The serotonin-norepinephrine-dopamine reuptake inhibitors, also known as triple reuptake inhibitors (TRIs), are emerging as promising antidepressants with greater potency and fewer side effects. Here, we determine an ensemble of structures of DAT in complex with fi…

  4. 43.

    Sommet A, Pathak A, Montastruc JL · Lancet (London, England) · 2009 · PMID 19249626

  5. 44.

    Tsai AG · Lancet (London, England) · 2009 · PMID 19249625

  6. 45.

    Axel AM, Mikkelsen JD, Hansen HH · Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2010 · PMID 20200509

    Tesofensine is a novel monoamine reuptake inhibitor that inhibits both norepinephrine, 5-HT, and dopamine (DA) reuptake function. Tesofensine is currently in clinical development for the treatment of obesity, however, the pharmacological basis for its strong effect in obesity management is not clarified. Using a rat model of diet-induced obesity (DIO), we characterized the pharmacological mechanisms underlying the appetite suppressive effect of tesofensine. DIO rats treated with tesofensine (2.0…

  7. 46.

    Doggrell SA · Expert opinion on investigational drugs · 2009 · PMID 19548858

    The incidence of obesity is increasing; this is of major concern, as obesity is associated with cardiovascular disease, stroke, type 2 diabetes, respiratory tract disease, and cancer. This evaluation is of a Phase II clinical trial with tesofensine in obese subjects. After 26 weeks, tesofensine caused a significant weight loss, and may have a higher maximal ability to reduce weight than the presently available anti-obesity agents. However, tesofensine also increased blood pressure and heart rate…

  8. 47.

    van de Giessen E, de Bruin K, la Fleur SE, van den Brink W, et al. · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2012 · PMID 21889317

    The novel triple monoamine inhibitor tesofensine blocks dopamine, serotonin and norepinephrine re-uptake and is a promising candidate for the treatment of obesity. Obesity is associated with lower striatal dopamine D2 receptor availability, which may be related to disturbed regulation of food intake. This study assesses the effects of chronic tesofensine treatment on food intake and body weight in association with changes in striatal dopamine D2/D3 receptor (D2/3R) availability of diet-induced o…

  9. 48.

    Hansen HH, Jensen MM, Overgaard A, Weikop P, et al. · Pharmacology, biochemistry, and behavior · 2013 · PMID 23932919

    Tesofensine is a triple monoamine reuptake inhibitor which inhibits noradrenaline, 5-HT and dopamine reuptake. Tesofensine is currently in clinical development for the treatment of obesity, however, the pharmacological basis for its strong and sustained effects in obesity management is not clarified. Tesofensine effectively induces appetite suppression in the diet-induced obese (DIO) rat partially being ascribed to an indirect stimulation of central dopamine receptor function subsequent to block…

  10. 49.

    Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, et al. · European journal of pharmacology · 2010 · PMID 20385125

    Tesofensine, a novel triple monoamine reuptake inhibitor, produces a significant weight loss in humans. The present study aimed at characterizing the weight-reducing effects of tesofensine in a rat model of diet-induced obesity. Sibutramine and rimonabant were used as reference comparators. Compared to baseline, long-term treatment with tesofensine (28 days, 1.0 or 2.5mg/kg, p.o.) resulted in a significant, dose-dependent and sustained weight loss of 5.7 and 9.9%, respectively. Sibutramine (7.5m…

  11. 50.
  12. 51.

    Astrup A, Madsbad S, Breum L, Jensen TJ, et al. · Lancet (London, England) · 2013 · PMID 23849924

  13. 52.

    Bentzen BH, Grunnet M, Hyveled-Nielsen L, Sundgreen C, et al. · Obesity (Silver Spring, Md.) · 2013 · PMID 23784901

    Tesofensine is a novel triple monoamine reuptake inhibitor which is in development for the treatment of obesity. Preclinical and clinical data suggest that appetite suppression is an important mechanism by which tesofensine exerts its robust weight reducing effect. Notably, the strong hypophagic response to tesofensine treatment is demonstrated to be linked to central stimulation of noradrenergic and dopaminergic neurotransmission. The sympathomimetic mode of action of tesofensine may also assoc…

  14. 53.

    Lehr T, Staab A, Tillmann C, Nielsen EØ, et al. · British journal of pharmacology · 2008 · PMID 17982477

    Tesofensine is a centrally acting drug under clinical development for Alzheimer's disease, Parkinson's disease and obesity. In vitro, the major metabolite of tesofensine (M1) displayed a slightly higher activity, which however has not been determined in vivo. The aims of this investigation were (i) to simultaneously accomplish a thorough characterization of the pharmacokinetic (PK) properties of tesofensine and M1 in mice and (ii) to evaluate the potency (pharmacodynamics, PD) and concentration-…

  15. 54.

    Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD · European journal of pharmacology · 2007 · PMID 17112503

    The changes of gene expression resulting from long-term exposure to monoamine antidepressant drugs in experimental animals are key to understanding the mechanisms of action of this class of drugs in man. Many of these genes and their products are either relevant biomarkers or directly involved in structural changes that are perhaps necessary for the antidepressant effect. Tesofensine is a novel triple monoamine reuptake inhibitor that acts to increase noradrenaline, serotonin, and dopamine neuro…

  16. 55.

    Lopez A, Gil-Lievana E, Gutierrez R · PloS one · 2025 · PMID 40554466

    This study investigated the sex-specific effects of commonly prescribed appetite suppressants on body weight and the manifestation of motor side effects, specifically stereotypy. Employing video recordings and DeepLabCut (DLC) for precise behavioral quantification, we analyzed stereotypy, defined as purposeless, repetitive motor behaviors, in male and female rats. Under control (saline) conditions, male rats exhibited a greater propensity for weight gain compared to females. However, in contrast…

  17. 56.

    Cheung BM, Cheung TT, Samaranayake NR · Therapeutic advances in drug safety · 2013 · PMID 25114779

    Obesity is a major health problem worldwide. Although diet and physical activity are crucial in the management of obesity, the long-term success rate is low. Therefore antiobesity drugs are of great interest, especially when lifestyle modification has failed. As obesity is not an immediate life-threatening disease, these drugs are required to be safe. Antiobesity drugs that have been developed so far have limited efficacies and considerable adverse effects affecting tolerability and safety. Ther…

  18. 57.

    Ioannides-Demos LL, Piccenna L, McNeil JJ · Journal of obesity · 2011 · PMID 21197148

    Past therapies for the treatment of obesity have typically involved pharmacological agents usually in combination with a calorie-controlled diet. This paper reviews the efficacy and safety of pharmacotherapies for obesity focusing on drugs approved for long-term therapy (orlistat), drugs approved for short-term use (amfepramone [diethylpropion], phentermine), recently withdrawn therapies (rimonabant, sibutamine) and drugs evaluated in Phase III studies (taranabant, pramlintide, lorcaserin and te…

  19. 58.

    Appel L, Bergström M, Buus Lassen J, Långström B · European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2014 · PMID 24239329

    Tesofensine (TE) is a novel triple monoamine re-uptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine, norepinephrine, and serotonin. In recent preclinical and clinical evaluations TE showed a robust anti-obesity effect, but the specific mechanism of this triple monoamine re-uptake inhibitor still needs to be further elucidated. This positron emission tomography (PET) study, using [¹¹C]βCIT-FE, aimed to assess the degree of…

  20. 59.

    Dodangeh S, Hasani-Ranjbar S. · 2025 · PMID 39712336

    Obesity is a pandemic problem that correlates with a cluster of metabolic factors leading to poor cardiovascular outcomes, morbidity, and an increased risk of overall mortality. It is necessary to approach obesity with a comprehensive treatment plan, which may involve lifestyle modifications (diet, exercise, and behavioral therapy) and pharmacological interventions. This article provides an overview of the mechanisms of action, efficacy, and safety of available long-term anti-obesity drugs and i…

  21. 60.

    Ullah MI, Tamanna S. · 2025 · PMID 40843857

    Obesity is a growing global health concern with widespread impacts on physical, psychological, and social well-being. Clinically, it is a major driver of type 2 diabetes (T2D), cardiovascular disease (CVD), non-alcoholic fatty liver disease (NAFLD), and cancer, reducing life expectancy by 5-20 years and imposing a staggering economic burden of USD 2 trillion annually (2.8% of global GDP). Despite its significant health and socioeconomic impact, earlier obesity medications, such as fenfluramine,…

  22. 61.

    Park C, Kim Y, Raygani S, Grunvald E. · 2025 · PMID 41019323

    Obesity has been historically a stubborn chronic metabolic disease, resistant to multiple therapeutic modalities. Although effective in the short-term for some people, lifestyle interventions have proven difficult to maintain in the long-term. Metabolic bariatric surgery is the most effective treatment for durable weight loss and improvement of obesity-related conditions but is invasive and vastly underutilized. For decades, patients and clinicians confronted a wide gap between lifestyle modific…

  23. 62.

    2022

    Abstract <h4>Objective</h4> To assess the safety and efficacy of Tesomet (tesofensine plus metoprolol) in adults with hypothalamic obesity, a rare disease with no approved therapy. <h4>Research Design and Methods</h4> Twenty-one adults with hypothalamic obesity (16 females, 5 males) were randomized to Tesomet (0.5 mg tesofensine/50 mg metoprolol) (n=14) or placebo (n=8) during a 24-week double-blind period. On completion of the double-blind period, 17 (81%) subjects (11 Tesomet; 6 placebo) enter…

  24. 63.

    Roth CL, Zenno A. · 2023 · PMID 37780616

    Hypothalamic obesity (HO) is a complex and rare disorder affecting multiple regulatory pathways of energy intake and expenditure in the brain as well as the regulation of the autonomic nervous system and peripheral hormonal signaling. It can be related to monogenic obesity syndromes which often affect the central leptin-melanocortin pathways or due to injury of the hypothalamus from pituitary and hypothalamic tumors, such as craniopharyngioma, surgery, trauma, or radiation to the hypothalamus. T…

  25. 64.

    Nicze M, Dec A, Borówka M, Krzyżak D, Bołdys A, Bułdak Ł, Okopień B. · 2024 · PMID 39125772

    Obesity is a chronic disease caused primarily by the imbalance between the amount of calories supplied to the body and energy expenditure. Not only does it deteriorate the quality of life, but most importantly it increases the risk of cardiovascular diseases and the development of type 2 diabetes mellitus, leading to reduced life expectancy. In this review, we would like to present the molecular pathomechanisms underlying obesity, which constitute the target points for the action of anti-obesity…

  26. 65.

    Angelidi AM, Belanger MJ, Kokkinos A, Koliaki CC, Mantzoros CS. · 2022 · PMID 35552683

    Recent insights into the pathophysiologic underlying mechanisms of obesity have led to the discovery of several promising drug targets and novel therapeutic strategies to address the global obesity epidemic and its comorbidities. Current pharmacologic options for obesity management are largely limited in number and of modest efficacy/safety profile. Therefore, the need for safe and more efficacious new agents is urgent. Drugs that are currently under investigation modulate targets across a broad…

  27. 66.

    Huynh K, Klose M, Krogsgaard K, Drejer J, Byberg S, Madsbad S, Magkos F, Aharaz A, Edsberg B, Tfelt-Hansen J, Astrup A, Feldt-Rasmussen U. · 2021

    Abstract Background: Structural damage to the hypothalamus often results in hypothalamic obesity characterized by rapid and severe weight-gain with increased risk of cardiovascular and metabolic morbidity and mortality. Currently, there are no approved or effective pharmacological treatments and conventional weight management remains largely ineffective. Objective: This RCT investigated safety and efficacy of Tesomet (co-administration of 0.5mg tesofensine and 50mg metoprolol) in hypopituitary p…

  28. 67.

    Kosmalski M, Deska K, Bąk B, Różycka-Kosmalska M, Pietras T. · 2023 · PMID 36767008

    Obesity is a growing civilization problem, associated with a number of negative health consequences affecting almost all tissues and organs. Currently, obesity treatment includes lifestyle modifications (including diet and exercise), pharmacologic therapies, and in some clinical situations, bariatric surgery. These treatments seem to be the most effective method supporting the treatment of obesity. However, they are many limitations to the options, both for the practitioners and patients. Often…

  29. 68.

    Dimitri P. · 2022 · PMID 35464063

    The hypothalamus is the centre of neuroendocrine regulation of energy homeostasis and appetite. Maldevelopment of, or damage to, the key hypothalamic nuclei disrupts the coordinated balance between energy intake and expenditure leading, to rapid and excessive weight gain. Hypothalamic obesity is compounded by a disruption of the hypothalamic-pituitary axis, sleep disruption, visual compromise, and neurological and vascular sequalae. Amongst suprasellar tumors, craniopharyngioma is the most commo…

  30. 69.

    Son JW, Kim S. · 2020 · PMID 33389955

    Obesity is among the leading causes of morbidity and mortality worldwide and its prevalence continues to increase globally. Because obesity is a chronic, complex, and heterogeneous disease influenced by genetic, developmental, biological, and environmental factors, it is necessary to approach obesity with an integrated and comprehensive treatment strategy. As it is difficult to achieve and sustain successful long-term weight loss in most patients with obesity through lifestyle modifications (e.g…

  31. 70.

    Shoemaker AH, Tamaroff J. · 2023 · PMID 36413492

    Hypothalamic obesity (HO) is defined as abnormal weight gain due to physical destruction of the hypothalamus. Suprasellar tumors, most commonly craniopharyngiomas, are a classic cause of HO. HO often goes unnoticed initially as patients, families, and medical teams are focused on oncologic treatments and management of panhypopituitarism. HO is characterized by rapid weight gain in the first year after hypothalamic destruction followed by refractory obesity due to an energy imbalance of decreased…

  32. 71.

    Rebello CJ, Greenway FL. · 2020 · PMID 31847611

    <b>Introduction</b>: Obesity is compounded by a neurobiology that is resistant to weight loss. Therefore, the development of pharmacotherapies to address the pathology underlying the dysregulation of energy homeostasis is critical.<b>Areas covered</b>: This review examines selected clinical trial evidence for the pharmacologic treatment of obesity and provides an expert opinion on anti-obesity drug development. The article includes the outcomes of anti-obesity medications that have been evaluate…

  33. 72.

    Müller T. · 2021 · PMID 33824605

    Parkinson's disease (PD) is the second most chronic neurodegenerative disorder worldwide. Deficit of monoamines, particularly dopamine, causes an individually varying compilation of motor and non-motor features. Constraint of presynaptic uptake extends monoamine stay in the synaptic cleft. This review discusses possible benefits of dopamine reuptake inhibition for the treatment of PD. Translation of this pharmacologic principle into positive clinical study results failed to date. Past clinical t…

  34. 73.

    Rahman QFA, Jufri NF, Hamid A. · 2023 · PMID 36873672

    Prader-Willi syndrome (PWS) is a rare genetic disorder due to lack of genes expression inherited from the paternal chromosome 15q11-q13 region usually from paternal deletions, maternal uniparental disomy 15 or imprinting defect. There are two different nutritional stages reported in an individual with PWS; first stage during infancy marked by feeding and growth difficulties and second stage where hyperphagia starts and leads to development of obesity. However, the exact mechanism of hyperphagia…

  35. 74.

    van Santen HM, Müller HL. · 2025 · PMID 40746184

    The hypothalamus is the key regulator of human energy balance. Hypothalamic dysfunction leads to (morbid) hypothalamic obesity, but may have many more consequences such as hypopituitarism, adipsia, disruption of the circadian rhythm, decreased energy expenditure, low core body temperature, and behavioral changes. Many patients with hypothalamic dysfunction experience chronic fatigue, increased daytime sleepiness, headaches, inactivity, and mood disorders, all of which may contribute to the devel…

  36. 75.

    Sauter ER, Agurs-Collins T. · 2024 · PMID 39409896

    Diets geared to reduce cancer risk in overweight and obese individuals focus on (1) caloric restriction (every day, some days, or most hours of each day); (2) changes in macronutrient intake; or (3) a combination of the prior two strategies. Diets generally fail because of nonadherence or due to limited sustained weight loss. This is in contrast to a diet supplemented with a weight loss medication, so long as the participant continues the medication or after bariatric surgery, in which adherence…

  37. 76.

    Chakhtoura M, Haber R, Ghezzawi M, Rhayem C, Tcheroyan R, Mantzoros CS. · 2023 · PMID 36992862

    Obesity is an epidemic and a public health threat. Medical weight management remains one of the options for the treatment of excess weight and recent advances have revolutionized how we treat, and more importantly how we will be treating obesity in the near future. Metreleptin and Setmelanotide are currently indicated for rare obesity syndromes, and 5 other medications (orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, semaglutide) are approved for non-syndromic obesity. Tirze…

  38. 77.

    Goldman VE, Naguib MN, Vidmar AP. · 2021 · PMID 34640558

    (1) Background: children with Prader-Willi syndrome (PWS) have high obesity rates due to hyperphagia and decreased metabolic rates. Although anti-obesity medications (AOMs) are prescribed to this population, there are no consensus guidelines on acceptability, safety, and efficacy. We present literature review and case series on AOMs in youth with PWS. (2) Methods: we performed PubMed review from January 2000 to April 2021 utilizing keywords: "Prader-Willi syndrome" or "PWS" and "medication" incl…

  39. 78.

    Kalinderi K, Goula V, Sapountzi E, Tsinopoulou VR, Tsinopoulou VR, Fidani L. · 2024 · PMID 38397265

    Obesity is a significant health problem with a continuously increasing prevalence among children and adolescents that has become a modern pandemic during the last decades. Nowadays, the genetic contribution to obesity is well-established. For this narrative review article, we searched PubMed and Scopus databases for peer-reviewed research, review articles, and meta-analyses regarding the genetics of obesity and current pharmacological treatment, published in the English language with no time res…

  40. 79.

    Müller HL. · 2025 · PMID 40426846

    <b>Introduction</b>: Craniopharyngiomas are rare sellar embryonic malformational tumors of low-grade histological malignancy. Despite high overall survival rates (92%), quality of life is frequently reduced due to adverse late effects caused by hypothalamic obesity. It is well known that morbid hypothalamic obesity is associated with the grade of hypothalamic damage. Accordingly, craniopharyngioma should be considered a paradigmatic disease, reflecting challenges in the diagnosis and treatment o…

  41. 80.

    Abdi Beshir S, Ahmed Elnour A, Soorya A, Parveen Mohamed A, Sir Loon Goh S, Hussain N, Al Haddad AHI, Hussain F, Yousif Khidir I, Abdelnassir Z. · 2023 · PMID 37712012

    <h4>Background</h4>Recently, many drugs have been approved for halting overweight and obesity-few types of research shifted to using Anti-obesity medications (AOM) solely for well-being and shape-keeping.<h4>Objective</h4>This narrative review's objective was to explore the use of AOM in relation to their medical indications, efficacy, and cardiovascular safety.<h4>Methods and materials</h4>We have conducted a narrative review of the literature on approved/non-approved AOM used for obesity and o…

  42. 81.

    Stemmer K, Müller TD, DiMarchi RD, Pfluger PT, Tschöp MH. · 2019 · PMID 31380808

    The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of…

  43. 82.

    Tak YJ, Lee SY. · 2021 · PMID 33410104

    <h4>Purpose of review</h4>As a chronic and relapsing disease, obesity impairs metabolism and causes cardiovascular diseases. Although behavioral modification is important for the treatment of obesity, it is difficult to achieve an ideal weight or sustain the process of long-term weight loss. Therefore, the obesity control guidelines strongly recommend lifestyle interventions along with medical treatment for patients who are overweight. There is sufficient evidence supporting that pharmacotherapy…

  44. 83.

    Marks DM, Pae CU, Patkar AA. · 2008 · PMID 19587855

    Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hope of creating medications with broader efficacy and/or quicker onset of action. The current review expl…

  45. 84.

    Vardanyan GS, Harutyunyan HS, Aghajanov MI, Vardanyan RS. · 2020 · PMID 33040605

    In recent decades, obesity has become a pandemic disease and appears to be an ultimate medical and social problem. Existing antiobesity drugs show low efficiency and a wide variety of side effects. In this review, we discuss possible mechanisms underlying brain-gut-adipose tissue axis, as well as molecular biochemical characteristics of various neurochemical regulators of body weight and appetite. Multiple brain regions are responsible for eating behavior, hedonic eating and food addiction. The…

  46. 85.

    Wharton S, Serodio KJ. · 2015 · PMID 25894803

    Since the 1980s, the prevalence of obesity has almost doubled worldwide. Treatments for obesity include lifestyle modification, medications and surgery. Newer anti-obesity medications have been shown to be effective at inducing initial weight management in addition to successful long-term weight maintenance. Historically, weight management medications have been associated with public safety concerns that have resulted in the majority being withdrawn from the market or never receiving medicinal a…

  47. 86.
  48. 87.

    Martin KA, Mani MV, Mani A. · 2015 · PMID 26001373

    Metabolic syndrome (MetS) is a cluster ofassociated metabolic traits that collectively confer unsurpassed risk for development of cardiovascular disease (CVD) and type 2 diabetes compared to any single CVD risk factor. Truncal obesity plays an exceptionally critical role among all metabolic traits of the MetS. Consequently, the prevalence of the MetS has steadily increased with the growing epidemic of obesity. Pharmacotherapy has been available for obesity for more than one decade, but with litt…

  49. 88.

    Krug O, Thomas A, Thevis M · Drug testing and analysis · 2026 · PMID 42320973

    Tesofensine (NS-2330) is a pharmacologically active compound with weight-reducing effects in obese patients. Although still under regulatory review, it has been marketed online as a dietary supplement promoted for weight management and metabolic enhancement. Due to its impact on body weight, tesofensine could be relevant in competitive sports, particularly in weight-class disciplines and sports where power-to-weight ratio is decisive. It is classified under "S6 stimulants" on the World Anti-Dopi…

Preprints (not yet peer-reviewed)

1
  1. 89.

    Perez CI, Luis-Islas J, Lopez A, Diaz X, Molina O, Arroyo B, Moreno MG, Lievana EG, Fonseca E, Castañeda-Hernández G, Gutierrez R. · 2023

    <h4>ABSTRACT</h4> Obesity is a major global health epidemic that has adverse effects on both the people affected as well as the cost to society. Several anti-obesity drugs that target GLP-1 receptors have recently come to the market. Here we describe the effects of tesofensine, a novel anti-obesity drug that acts as a triple monoamine neurotransmitter reuptake inhibitor. We investigated its effects on weight loss and underlying neuronal mechanisms in mice and rats using various techniques. These…

Curated sources on file

2
  1. 1.
  2. 2.

Continue reading